Alector Inc

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alector Inc reports robust earnings, advances Alzheimer's therapy development

Alector Inc's Q2 2023 earnings call highlighted strong financial performance, progress in late-stage clinical programs, and a focus on immuno-neurology research.
The company faces challenges in trial management and disease progression variability but benefits from a solid cash position and collaboration revenue.
Opportunities lie in upcoming milestones, conference participation, and the potential of AL002 therapy, positioning Alector for continued growth and innovation.

Alector Inc reports strong Q4 performance and advances in neurodegenerative treatments

Alector Inc's Q4 performance reflects significant achievements in late-stage programs, strong financial standing, and positive patient engagement, underlining progress in neurodegenerative disease treatment.
The company's strengths in immuno-neurology, blood-brain barrier technology, and strategic partnerships position them well for addressing Alzheimer's disease and exploring accelerated approval pathways.
Challenges in trial design, biomarker assessment, and resource allocation require careful navigation, while opportunities in therapeutic delivery enhancement and disease progression slowing offer avenues for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GlaxoSmithKline

Alector (ALEC) stock is rocketing higher on Friday after the biotechnology company announced a partnership with GlaxoSmithKline (GSK). The post ALEC Stock: 12 Things to Know About Alector as GSK News Sends It Rocketing Higher appeared first on InvestorPlace.

ALEC Stock: 12 Things to Know About Alector as GSK News Sends It Rocketing Higher

Alector Inc (NASDAQ: ALEC) and GlaxoSmithKline plc (NYSE: GSK) have announced a global collaboration for the development and commercialization of two monoclonal antibodies designed to elevate progranulin (PGRN) levels.  PGRN is a crucial regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders.

Alector Shares Jump On $2.2B Immuno-Neurology Development Pact With GSK

SOUTH SAN FRANCISCO, Calif. and LONDON, July 02, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GlaxoSmithKline plc (LSE/NYSE: GSK), today announced a strategic global collaboration for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels. PGRN is a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, making it one of the most attractive genetically validated targets for the development of new immuno-neurology treatments.

Alector and GSK announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases

SOUTH SAN FRANCISCO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in fireside chats at the following upcoming virtual investor conferences:

Alector to Present at Upcoming Virtual Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it will host a virtual key opinion leader event focused on frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) on Friday, June 11, 2021 at 10:30 a.m. ET.

Alector to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia on June 11, 2021

Alector is doing pioneering work in various neurodegenerative diseases including Alzheimer's.

Alector: Pioneering Approach In CNS Diseases

Alector (ALEC) delivered earnings and revenue surprises of 2.94% and -35.93%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced business updates and financial results for the first quarter ended March 31, 2021.

Alector Reports 2021 First Quarter Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in a fireside chat at Stifel's 3rd Annual CNS Day on Thursday, April 1, 2021, at 9:30 a.m. ET.

Alector to Present at Stifel's 3rd Annual CNS Day

Clovis Oncology

Marker Therapeutics Inc

Clovis Oncology, Inc. (NASDAQ: CLVS), Marker Therapeutics, Inc. (NASDAQ: MRKR) and Alector, Inc. (NASDAQ: ALEC) are among the biggest biotech gainers Friday. Clovis Jumps On Ovarian Cancer Data: Clovis announced positive results for the Phase 3 study of Rubraca in ovarian cancer.

Why Clovis Oncology, Marker Therapeutics, Alector Are Rallying Friday

SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in a fireside chat at the Barclays Global Healthcare Conference on Thursday, March 11, 2021, at 2:25 p.m. ET.

Alector to Present at the Barclays Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the first participant has been dosed in INVOKE-2, a Phase 2 clinical study evaluating the efficacy and safety of AL002 in slowing disease progression in individuals with early Alzheimer's disease. AL002 is an investigational, humanized monoclonal antibody that targets triggering receptor expressed on myeloid cells 2 (TREM2), a transmembrane receptor protein that is expressed on a subset of innate immune cells and selectively on microglia, which serve as the immune cells in the brain. The AL002 clinical program is being developed in collaboration with AbbVie.

Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer's Disease

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that chief business officer (CBO), Sabah Oney, Ph.D., will be leaving the Company to pursue other opportunities. Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer, will serve as interim CBO, overseeing the business development, finance, communications, facilities, and IT departments. The transition will be effective as of February 1, 2021 and Dr. Oney will remain as an employee and advisor to Alector until May 3, 2021.

Alector Announces Departure of Chief Business Officer

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today provided a preview of its planned clinical and research priorities for 2021.

Alector Provides 2021 Corporate Portfolio Update

Alector is a leader in neuroimmunology drug development. This has enabled the company to build a pipeline of medicines pursuing large and important markets from dementia and Alzheimer's.

Alector: Activating Microglia To Treat Neurodegeneration

Alector, Inc (Nasdaq: ALEC) is a clinical-stage biopharmaceutical company focused on immuno-neurology, immune dysfunction studies related to degenerative brain disorders. Alector has 4-clinical phase therapeutics entirely targeting primarily neurological diseases including Alzheimer's and Frontotemporal Dementia. Alector also has 2-preclinical therapeutics, and 8 in the research phase.

Alector: AL001's Phase 3 Initiation/Phase 2 Readout In 2021, $462M In Cash, And AbbVie's Promising Support, +38% Upside

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., chief business officer of Alector, will participate in a fireside chat at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020, at 4:40 p.m. ET.

Alector to Present at the Stifel 2020 Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced corporate updates and financial results for the third quarter ended September 30, 2020.

Alector Reports Third Quarter 2020 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that an independent arbitrator issued an interim, confidential decision in favor of the company in its dispute with Asa Abeliovich, M.D., Ph.D., founder and chief executive officer of Prevail Therapeutics. The arbitrator found Dr. Abeliovich liable for breach of his consulting agreement with Alector and for spoliation based on his destruction of documents relevant to the proceeding. The arbitrator awarded damages for breach of the agreement, and sanctions for the spoliation as well as violation of orders during the proceeding. The monetary amounts of the damages and sanctions will be determined in further proceedings.

Alector Provides Update on Arbitration Proceedings with Dr. Asa Abeliovich

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of the Company's immuno-oncology team will provide an overview of the company's early-stage immuno-oncology research, specifically the AL008 development program, at two upcoming virtual scientific meetings.

Alector to Highlight Early-Stage Cancer Programs at Upcoming Scientific Forums

Alector (ALEC) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Alector (ALEC) Surges: Stock Moves 6.9% Higher

SOUTH SAN FRANCISCO, Calif., Sept.  03, 2020  (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of management will participate in fireside chats at the following upcoming virtual investor conferences:

Alector to Participate at Virtual Investor Conferences in September

Ameriprise Financial

Las Vegas Sands

Royal Caribbean Cruises

Service Corp

United Continental Hlds

Welltower

Zillow

Baby boomers have a reputation of being old and therefore irrelevant. However, this powerful and influential generation can spark huge demand for many stocks to buy.

9 Stocks to Buy to Profit off the Baby Boomer Generation

Alector (ALEC) delivered earnings and revenue surprises of -11.54% and -64.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) Reports Q2 Loss, Misses Revenue Estimates

SOUTH SAN FRANCISCO, Calif., Aug.  11, 2020  (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced corporate updates and financial results for the second quarter ended June 30, 2020.

News for Alector Inc Stock (ALEC)